• Date:29 Jun 2020
  • Views:21
  • Downloads:0
  • Size:424.64 KB





systems TDDS are dosageforms designed to facilitate thepassage of therapeuticquantities of drug substancesthrough the skin and into the.
general circulation for systemic SKIN STRUCTURE The epidermis almost impermeable deadlayer of cells It controls the percutaneousabsorption of drugs and other chemical.
The dermis matrix of connective tissuemade up of fibrous proteins collagen elastin reticulin embedded in mucopolysaccharide It also contains nerves blood vessels andlymphatic vessels and appendages such as.
sweat glands Branches from arterial plexus deliver blood tosweat glands hair follicles subcutaneous fatand the dermis DRUG TRANSPORT.
THROUGH THE SKIN The epidermis is very selective and itprovides major control for the permeationof the skin Drug entry into the skin can occur through.
three possible routes Through the hair follicles Via the sweat duct Across the stratum corneum FACTORS AFFECTING.
PERCUTANEOUS DRUG ABSORPTION Concentration of drug The amount of drugabsorbed per unit surface area per time increases withincrease in concentration of drug in the TDDS Surface area of application More drug is.
absorbed from TDDS with larger size Affinity of drug for skin and for the base Physicochemical attraction of drug should be higher forthe skin than for the base PC should be adequate Molecular weight of the drug Drugs of molecular.
weight MW between 100 800 can permeate the skinprovided the lipid solubility is adequate The idealmolecular size of drugs for TDDS is 100 400 PARTITION COEFFICIENT Compounds with.
partition coefficientsindicating an ability todissolve in both oil andwater i e log P of 1 3 would permeate the skin.
relatively rapidly 6 29 20 7 FACTORS AFFECTINGPERCUTANEOUS DRUG ABSORPTION Hydration of the skin The skin should.
be adequately hydrated for efficientdrug absorption from TDDS Site of application Better delivery isachieved when TDDS is applied to sitewith thin horny layer see below .
Duration of application The longer themedicated application remains on thegreater the total drug absorbed VARYING SKIN THICKNESSESAT DIFFERENT BODY REGIONS .
Rushmer R F Buettner K J K Short J M Odland G F The skin Science 1966 154 343 348 FORMULATION OFThe main components of TDDS The drug.
The base delivery device The Percutaneous absorptionenhancers 6 29 20 10 DRUGS IN TDDS.
Examples of drugs meeting the criteria fordelivery in TDDS are 1 Clonidine Catapress TTS Four layeredpatch for antihypertensive delivery of clonidineover 7 days.
2 Estradiol Estraderm Norvatis Four layered patch and Vivelle Norvatis three layered patch Both are designed to release 17 estradiol continuously 3 Nicotine Habitrol Norvatis consumer .
Multilayered patch for controlling nicotinedependence 6 29 20 11 DELIVERY DEVICES These are also known as transdermal.
patches Designed to support the passage of drugsubstances from the surface of the skinthrough its various layers into the systemiccirculation .
The two most common types are the monolithic systems membrane controlled TDS 6 29 20 12 MONOLITHIC SYSTEMS.
Monolithic systems The designincorporates a drug matrix layerbetween the device backing andthe frontal layers The polymer matrix controls the.
rate at which the drug is releasedfor percutaneous absorption 6 29 20 13 MEMBRANE CONTROLLED Membrane controlled systems .
Designed to contain adrug reservoir or pouch usually in liquid or gel form a rate controlling membrane abacking adhesive and.
protecting layers 6 29 20 14 MEMBRANE CONTROLLEDSYSTEMS CONT These systems may be prepared.
pre constructing the delivery unit filling in the drug reservoir and aprocess of lamination whichinvolves a continuous process ofconstruction dosing and sealing .
6 29 20 15 ADVANTAGES OF TDDS Avoidance of gastrointestinal absorptiondifficulties caused by pH enzyme and druginteraction with food etc .
Suitable in cases where oral route is notappropriate as in vomiting diarrhea Avoidance of the first pass metabolism in the Avoidance of the inconveniences of parenteral therapy Improved patient compliance due to the lower frequency.
of dosing 6 29 20 16 DISADVANTAGES OF TDDS Onlyrelatively potent drugscan be so formulated.
Incidence of contactdermatitis has beenreported in some patients6 29 20 17 PERCUTANEOUS.
ABSORPTION ENHANCERS Chemical dimethyl acetamideenhancers dimethyl formamideAgents which.
reversibly alter dimethyl sulfoxidethe physico Ethanolnature of the oleic acidstratum polyethylene glycolscorneum to.
reduce its propylene glycol sodium laurylsulphate diffusionalresistance 6 29 20 18 NEW ENHANCERS.
Over the past 2 decades several chemical skinpermeation enhancers have been designed synthesized and evaluated Azone 1 dodecylazacycloheptan 2 one... SEPA 2 n nonyl 1 3 dioxolane .
1 2 decylthio ethyl azacyclope... HPE 101 4 decyloxazolid 2 one DermacTM SR 38 dodecyl N N dimethylamino isopropionate DDAIP NexACT 88 6 29 20 19.
STRATEGIES FOR REDUCTION Adverse skin responses tochemical exposure are variable may be immediate or delayed Long or short duration .
Irritant or allergic 6 29 20 21 ADVERSE LOCAL REACTIONS ANDSTRATEGIES FOR REDUCTION Dermatologicaland transdermal formulations.
contain a complex mixture of active and inactiveingredients adverse reactions may be due to a formulation additive excipient and not necessarily an active compound it is well known that the pressure sensitive adhesive.
used to produce intimate contact with the skin is moreoften the source of cutaneous reactivity not the drug many of the inactive ingredients used in topicalpharmaceutical dosage forms have the ability to alterthe barrier function of the skin.
6 29 20 22 MITIGATING ADVERSELOCAL REACTION Plant extracts reputed to possess anti irritant propertiesand have been recommended for use in cosmetic.
formulations Tea tree oil Borage seed oil Paraguay tea extract Kola nut extract.
Oil of rosemary Lavender oil 6 29 20 23 MITIGATING ADVERSELOCAL REACTION .
Strontium nitrate Cosmederm 7TM reduce the sensory irritation and erythemaproduced following application of a 70 freeglycolic acid peel histamine induced itch A combination of compounds oleic acid .
a short chain length alcohol and aglycol all gelled with a carbomer has been found to reduce chemical induced inflammation associated with thetopical application of several CELLEDIRM .
Cellegy Pharmaceuticals Inc 6 29 20 24 PERCUTANEOUS ABSORPTIONENHANCERS CONT Ionophoresis Delivery of charged compounds.
across the skin membrane using appliedelectrical field E g Lindocaine Dexamethasone Insulin.
verapamil propranolol 6 29 20 25 PERCUTANEOUS ABSORPTIONENHANCERS CONT .
Sonophoresis Use of High frequencyultrasound to enhance transdermaldrug delivery Therapeutic frequency ultrasound 1 3MHz is most commonly used at intensity.
in the range of 0 2W cm2 Therapeutic ultrasound has been attempted toenhance transdermal transport of more than6 29 20 26 MECHANISMS OF.
SONOPHORETIC TRANSPORT Cavitation Acoustic streaming around Electroporation Thermoporation.
6 29 20 27 MECHANISMS OFSONOPHORETIC Ultrasound exposure in the therapeutic rangecauses cavitation in the keratinocytes of the.
stratum corneum Oscillations of the ultrasound inducedcavitation bubbles near the keratinocyte lipidbilayer interfaces may in turn causeoscillations in the lipid bilayers causing.
structural disorder of the SC lipids Shock waves generated by the collapse ofcavitation bubbles at the interfaces may alsocontribute to the structure disordering effect 6 29 20 28.
TO INSULIN6 29 20 30 AGENTS FOR APPLICATIONOF SONOPHORESIS steroidal anti inflammatory drugs.
hydrocortisone dexamethasone non steroidal anti inflammatory drugssuch as salicylates and ibuprofen anesthetic agents such as lidocaine.
proteins such as insulin 6 29 20 31 EXPERIMENTAL SET UP FORSONOPHORESIS DELIVERY6 29 20 32.
adverse reactions may be due to a formulation additive (excipient) and not necessarily an active compound. it is well known that the pressure sensitive adhesive used to produce intimate contact with the skin is more often the source of cutaneous reactivity & not the drug.

Related Presentations

FTS CSP absorbsi percutan dan transdermal

η= viskositas (dyne cm-2) r= jari-jarimolekul (cm/molekul) N= bilangan Avogadro (6,02 X 1023 molekul/mol) ...

4 Views0 Downloads

Vaginal drug delivery systems

SISTEM PENGHANTARAN OBAT MELALUI VAGINA Oleh : Adi Yugatama, S.Farm., Apt. Jurusan Farmasi FKIK UNSOED 2012 * * * * * * * * * * * * * * Contents: Pendahuluan Kelebihan dan Kelemahan Anatomi dan Fisiologi Vagina Faktor yang mempengaruhi absorpsi obat di vagina Perkembangan Penghantaran Obat Melalui Vagina Evaluasi In vitro & in vivo Formulasi Vagina Kesimpulan * Penghantaran obat melalui vagina ...

5 Views0 Downloads


Formulation and evaluation of muco adhesive tablet of timololmaleate. Formulation and in vitro evaluation of mucoadhesivebuccal tablets of diltiazem. Study of various polymers in buccal drug delivery system.

21 Views0 Downloads

Gastroretentive Drug Delivery System PharmaQuesT

gastroretentive. drug delivery system. ... Carbonates or bicarbonates, which react with gastric acid or any other acid (e.g., citric or tartaric) present in the formulation to produce CO. 2, are usually incorporated in the dosage form, ... Adhesive. High Turn Over Rate of MUCUS LAYER. Thick Mucus Layer.

13 Views0 Downloads

Best Practices for Intrathecal Drug Delivery

In early 2006, Medtronic received an increase in the rate of spontaneous reports of patient death within 3 days of implant and initiation of intrathecal drug therapy. From 1998-2007 a total of 88 patients died within 3 days of pump implant, refill, replacement, reprogramming, dose change or catheter revision.

10 Views0 Downloads

Oral Sustained and Controlled Drug Delivery System

The transit time of drug must be in the absorptive areas of the GI tract is about 8-12 hrs. If the . rate of absorption is below 0.17/hr and above the 0.23/hr . then it is . difficult to prepare sustained release formulation. As the . rate limiting step . in drug delivery from a sustained-release system is its

8 Views0 Downloads

Ocular Drug Delivery System ADI YUGATAMA

POINT PENTING UNTUK OPTIMASI PENGHANTARAN OBAT MELALUI MATA. Improving ocular contact time. Enhancing corneal permeability. Enhancing site specificity. Mekanisme Absorpsi Melalui Mata. Non-Corneal Absorption. Corneal Absorption. Penetrasi melalui Sclera & Conjuctivauntuk masuk ke dalam jaringan mata.

2 Views0 Downloads

National Drug Overdose Deaths Involving Any Drug Number

National Drug Overdose Deaths—Number Among All Ages, by Gender, 1999-2018. More than 67,300 Americans died from drug-involved overdose in 2018, including illicit drugs and prescription opioids. The figure above is a bar and line graph showing the total number of U.S. drug overdose deaths involving any illicit or prescription opioid drug from ...

36 Views0 Downloads

Drug Use Drug Control and Human Rights Issues Raised at

Allow opioids and cocaine for medical reasons: controlled growth, physician prescription. Cultivation, sale and transportation for non-medical reasons would be considered criminal activity. Does not demand that personal use is criminal. Main thrust is against production, sale and especially organized crime

12 Views0 Downloads

Capacity Management in Health Delivery Systems

Focused Operations Management for Health Services Organizations Based on the book by Boaz Ronen Joseph Pliskin Shimeon Pass BUDT 758O, Jan. 2009 Professor B. L. Golden The Modern

11 Views0 Downloads

Explicit Instructional Delivery Modeling Learning

The answer is easy to find in the reading. The words used to make up the question are right there in the same sentence. Think & Search - The answer to the question is in the reading/ The answer is made up of information that comes from more than one sentence or paragraph.

22 Views0 Downloads

AAH Reinvented Operations and Care Delivery Core Team

7-Day Average Supply of COVID Rapid Testing Kits Develop Staff COVID Screening Protocols and Process (e.g., Cross-Team Collaboration Opportunity) Criteria V: Infection Control. Develop/ Define Facility Infection Control Committee Develop Patient, Public, Consumer, & Staff Communication Plan

16 Views0 Downloads